Roivant Sciences Ltd (NASDAQ:ROIV) has earned an average rating of “Buy” from the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $13.33.
ROIV has been the subject of several recent research reports. Truist assumed coverage on Roivant Sciences in a report on Tuesday, October 26th. They issued a “buy” rating and a $15.00 price target for the company. SVB Leerink reaffirmed a “buy” rating on shares of Roivant Sciences in a research note on Sunday, December 5th. Citigroup began coverage on Roivant Sciences in a research note on Wednesday, October 27th. They issued a “buy” rating and a $11.00 price objective for the company. The Goldman Sachs Group began coverage on Roivant Sciences in a report on Wednesday, December 15th. They issued a “buy” rating and a $15.00 target price for the company. Finally, HC Wainwright began coverage on Roivant Sciences in a report on Monday, November 8th. They set a “buy” rating and a $14.00 price target for the company.
Shares of ROIV stock opened at $7.95 on Friday. Roivant Sciences has a twelve month low of $5.80 and a twelve month high of $16.76. The stock has a fifty day moving average price of $9.93.
About Roivant Sciences
Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.
Featured Article: Penny Stocks, What You Need To Know
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.